Advancements in Gastroenterology: A Weekly Review
Gastroenterologia
Advances in Gastrointestinal Oncology and IBD Management
This week's episode covers groundbreaking research in gastrointestinal oncology including sintilimab and zolbetuximab trials, long-term mirikizumab data for UC, and important updates in pancreatitis and MASLD management.
Accedi o Registrati per ascoltare questo episodio
Bibliografia
1. Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial.
Authors: Xu J, Jiang H, Pan Y, et al.
Journal: JAMA, 2023 Dec 5
PMID: 38051328
DOI: 10.1001/jama.2023.19918
2. Inflammatory bowel disease biomarkers.
Authors: Liu D, Saikam V, Skrada KA, et al.
Journal: Medicinal research reviews, 2022 Sep
PMID: 35603998
DOI: 10.1002/med.21893
3. American College of Gastroenterology Guidelines: Management of Acute Pancreatitis.
Authors: Tenner S, Vege SS, Sheth SG, et al.
Journal: The American journal of gastroenterology, 2024 Mar 1
PMID: 38857482
DOI: 10.14309/ajg.0000000000002645
4. Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study.
Authors: Sands BE, Clemow DB, D'Haens G, et al.
Journal: Inflammatory bowel diseases, 2026 Jun 1
PMID: 41777218
DOI: 10.1093/ibd/izag007
5. Cholangiocarcinoma.
Authors: Razumilava N, Gores GJ
Journal: Lancet (London, England), 2014 Jun 21
PMID: 24581682
DOI: 10.1016/S0140-6736(13)61903-0
6. First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.
Authors: Shitara K, Shoji H, Fazio N, et al.
Journal: Nature medicine, 2026 Jun
PMID: 41840238
DOI: 10.1038/s41591-026-04306-9
7. Effect of photobiomodulation on pain and quality of life in fibromyalgia syndrome: a systematic review.
Authors: G A S, Maiya GA, Shetty S, et al.
Journal: Lasers in medical science, 2026 Jun 23
PMID: 42334638
DOI: 10.1007/s10103-026-04930-4
8. AGA Clinical Practice Update on Risk Stratification and Emerging Surveillance Strategies for Hepatocellular Carcinoma: Expert Review.
Authors: Rich NE, Villanueva A, Marrero JA, et al.
Journal: Gastroenterology, 2026 Jun
PMID: 42017860
DOI: 10.1053/j.gastro.2026.03.006
9. Clostridium difficile in inflammatory bowel disease.
Authors: Alhobayb T, Ciorba MA
Journal: Current opinion in gastroenterology, 2023 Jul 1
PMID: 37265220
DOI: 10.1097/MOG.0000000000000949
10. Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026.
Authors: Akuta N, Kogiso T, Ikejima K, et al.
Journal: Journal of gastroenterology, 2026 Jun
PMID: 42120590
DOI: 10.1007/s00535-026-02408-2
Authors: Xu J, Jiang H, Pan Y, et al.
Journal: JAMA, 2023 Dec 5
PMID: 38051328
DOI: 10.1001/jama.2023.19918
2. Inflammatory bowel disease biomarkers.
Authors: Liu D, Saikam V, Skrada KA, et al.
Journal: Medicinal research reviews, 2022 Sep
PMID: 35603998
DOI: 10.1002/med.21893
3. American College of Gastroenterology Guidelines: Management of Acute Pancreatitis.
Authors: Tenner S, Vege SS, Sheth SG, et al.
Journal: The American journal of gastroenterology, 2024 Mar 1
PMID: 38857482
DOI: 10.14309/ajg.0000000000002645
4. Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study.
Authors: Sands BE, Clemow DB, D'Haens G, et al.
Journal: Inflammatory bowel diseases, 2026 Jun 1
PMID: 41777218
DOI: 10.1093/ibd/izag007
5. Cholangiocarcinoma.
Authors: Razumilava N, Gores GJ
Journal: Lancet (London, England), 2014 Jun 21
PMID: 24581682
DOI: 10.1016/S0140-6736(13)61903-0
6. First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.
Authors: Shitara K, Shoji H, Fazio N, et al.
Journal: Nature medicine, 2026 Jun
PMID: 41840238
DOI: 10.1038/s41591-026-04306-9
7. Effect of photobiomodulation on pain and quality of life in fibromyalgia syndrome: a systematic review.
Authors: G A S, Maiya GA, Shetty S, et al.
Journal: Lasers in medical science, 2026 Jun 23
PMID: 42334638
DOI: 10.1007/s10103-026-04930-4
8. AGA Clinical Practice Update on Risk Stratification and Emerging Surveillance Strategies for Hepatocellular Carcinoma: Expert Review.
Authors: Rich NE, Villanueva A, Marrero JA, et al.
Journal: Gastroenterology, 2026 Jun
PMID: 42017860
DOI: 10.1053/j.gastro.2026.03.006
9. Clostridium difficile in inflammatory bowel disease.
Authors: Alhobayb T, Ciorba MA
Journal: Current opinion in gastroenterology, 2023 Jul 1
PMID: 37265220
DOI: 10.1097/MOG.0000000000000949
10. Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026.
Authors: Akuta N, Kogiso T, Ikejima K, et al.
Journal: Journal of gastroenterology, 2026 Jun
PMID: 42120590
DOI: 10.1007/s00535-026-02408-2
